New

North America Diltiazem Market

2021

North America Diltiazem Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Capsules, Injection, and Tablets) and Application (Angina, Hypertension, and Others)

Publication Month: Oct 2021 | Report Code: TIPRE00025364 | No. of Pages: 117 | Category: Pharmaceuticals | Status: Published

Market Insights

North America Diltiazem Market to Grow at a CAGR of 12.5% to reach US$ 369.22 million Million from 2021 to 2028

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!

The North America diltiazem market is expected to reach US$ 369.22 million by 2028 from US$ 161.53 million in 2021; it is estimated to grow at a CAGR of 12.5% from 2021 to 2028.


Rise in government initiatives for promotion, increase in the prevalence of cardiovascular diseases, and rise in the elderly population with heart diseases worldwide are expected to boost the market growth over the years. However, the side effects of Diltiazem on consumption are likely to impact the market's growth in the coming years negatively.

Diltiazem has potential use in a wide variety of cardiovascular disorders. According to the World Health Organization, cardiovascular diseases (CVDs) are the number one cause of death worldwide. CVDs are a major cause of morbidity and affect more people than any other disease. Tobacco consumption, unhealthy diet, and physical inactivity are major lifestyle factors that increase the risk of heart attacks and strokes. In addition, other risk factors that can lead to cardiovascular diseases are high blood pressure, diabetes, and increased cholesterol levels. The Centers for Disease Control and Prevention (CDC) estimated that around 2.7–6.1 million people were suffering from Atrial fibrillation (AFib) in the US in 2019. Every year, over 454,000 hospitalizations and about 158,000 deaths are reported due to AFib in the US. The calcium channel blockers diltiazem (Cardizem) and verapamil (Calan and Apoptin) effectively control the initial ventricular rate in patients with atrial fibrillation. These agents are given intravenously in bolus doses until the ventricular rate becomes slower.

Furthermore, Diltiazem reduces conduction in the atrioventricular node, which is also useful for heart rate control in patients with atrial fibrillation. Thus, the increasing prevalence of atrial fibrillation across the globe drives the diltiazem market. Also, the elderly population is more prompt to have atypical presentations, comorbid conditions, and unfavorable outcomes. Structural and functional changes in the cardiovascular system associated with aging are major causes of cardiovascular diseases. Therefore, the rising geriatric population worldwide is leading to an increase in the incidence of cardiovascular disease, bolstering the growth of the diltiazem market.

In North America, the US was highly influenced by the eruption of the COVID-19 pandemic. The COVID-19 pandemic has created technological shifts crucial to providing better care. Given the current pandemic and the need for practicality, the drugs should ideally be FDA approved so they can be rapidly repurposed for COVID-19 treatment. SARS-CoV requires Ca2+ ions for host cell entrance, and based on the connection between SARS-CoV and SARS-CoV-2, it is very likely that the exact necessities exist for both viruses. Moreover, as per the recent report of bioRxiv published in July 2020, there is evidence that calcium channel blockers (CCB) inhibit viral infections at the cell entry level. Therefore, treatment with verapamil or Diltiazem inhibits viral infection. Hypertension was among the general comorbidities seen in COVID-19 infected patients. Diltiazem may be helpful to treat hypertension associated with COVID-19. Since the COVID-19 outbreak reached the pandemic status, the entire global supply chain has been affected; however, various pharmaceutical companies are developing vaccines and drugs to combat the pandemic. Therefore, COVID-19 has had a substantial positive impact on the diltiazem market.

Get more information on this report :


NORTH AMERICA DILTIAZEM MARKET SEGMENTATION

By Product Type

  • Tablet
  • Capsules
  • Injection

By Application

  • Hypertension
  • Angina
  • Others

By Country

  • US
  • Canada
  • Mexico

Company Profiles

  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd
  • MYLAN N.V.
  • Pfizer Inc.
  • Sandoz (Novartis AG)
  • Sun Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC
  • Zydus Cadila
  • Glenmark
  • Athenex

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 North America Diltiazem Market – By Product Type

1.3.2 North America Diltiazem Market – By Application

1.3.3 North America Diltiazem Market – By Country

2. North America Diltiazem Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Diltiazem Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America – PEST Analysis

4.3 Experts Opinion

5. Diltiazem Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increase in Cardiovascular Disease Incidence

5.1.2 Increasing Elderly Population

5.2 Market Restraints

5.2.1 Side Effects of Diltiazem

5.3 Future Trends

5.3.1 Recent Developments in Market

5.4 Impact Analysis

6. Diltiazem Market – North America Analysis

6.1 North America Diltiazem Market Revenue Forecast and Analysis

7. Diltiazem Market Analysis and Forecasts to 2028 – Product Type

7.1 Overview

7.2 Diltiazem Market Share by Product Type 2021 & 2028 (%)

7.3 Capsules

7.3.1 Overview

7.3.2 Capsules Market Revenue and Forecast to 2028 (US$ Mn)

7.4 Injection

7.4.1 Overview

7.4.2 Injection Market Revenue and Forecast to 2028 (US$ Mn)

7.5 Tablets

7.5.1 Overview

7.5.2 Tablet Market Revenue and Forecast to 2028 (US$ Mn)

8. Diltiazem Market Analysis and Forecasts to 2028 – Application

8.1 Overview

8.2 Diltiazem Market Share by Application 2021 & 2028 (%)

8.3 Angina

8.3.1 Overview

8.3.2 Angina Market Revenue and Forecast to 2028 (US$ Mn)

8.4 Hypertension

8.4.1 Overview

8.4.2 Hypertension Market Revenue and Forecast to 2028 (US$ Mn)

8.5 Others

8.5.1 Overview

8.5.2 Others Market Revenue and Forecast to 2028 (US$ Mn)

9. Diltiazem Market – North America Analysis

9.1 North America: Diltiazem Market

9.1.1 Overview

9.1.2 North America: Diltiazem Market, by Country, 2021 & 2028 (%)

9.1.2.1 US: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.1.1 US: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.1.2 US Diltiazem Market, by Product Type– Revenue and Forecast to 2028 (USD Million)

9.1.2.1.3 US Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)

9.1.2.2 Canada: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.2.1 Canada: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.2.2 Canada Diltiazem Market, by Product Type– Revenue and Forecast to 2028 (USD Million)

9.1.2.2.3 Canada Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)

9.1.2.3 Mexico: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.3.1 Mexico: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.3.2 Mexico Diltiazem Market, by Product Type– Revenue and Forecast to 2028 (USD Million)

9.1.2.3.3 Mexico Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)

10. Impact Of COVID-19 Pandemic on North America Diltiazem Market

10.1 North America: Impact Assessment of COVID-19 Pandemic

11. Diltiazem Market–Industry Landscape

11.1 Overview

11.2 Recent Growth Strategies in The Diltiazem Market

12. Company Profiles

12.1 Bausch Health Companies Inc.

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Teva Pharmaceutical Industries Ltd

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 MYLAN N.V.

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4

12.5 Pfizer Inc.

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Sandoz (Novartis AG)

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 Sun Pharmaceutical Industries Ltd

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 Hikma Pharmaceuticals PLC

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6 Key Developments

12.9 Zydus Cadila

12.9.1 Key Facts

12.9.2 Business Description

12.9.3 Products and Services

12.9.4 Financial Overview

12.9.5 SWOT Analysis

12.9.6 Key Developments

12.10 Glenmark

12.10.1 Key Facts

12.10.2 Business Description

12.10.3 Products and Services

12.10.4 Financial Overview

12.10.5 SWOT Analysis

12.10.6 Key Developments

12.11 Athenex

12.11.1 Key Facts

12.11.2 Business Description

12.11.3 Products and Services

12.11.4 Financial Overview

12.11.5 SWOT Analysis

12.11.6 Key Developments

13. Appendix

13.1 About The Insight Partners

13.2 Glossary of Terms


LIST OF TABLES

Table 1. US Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

Table 2. US Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)

Table 3. Canada Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

Table 4. Canada Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)

Table 5. Mexico Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

Table 6. Mexico Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)

Table 7. Glossary of Terms, Diltiazem Market

LIST OF FIGURES

Figure 1. Diltiazem Market Segmentation

Figure 2. Diltiazem Market Segmentation, By Country

Figure 3. North America Diltiazem Market Overview

Figure 4. Tablets Held the Largest Share of the Product Segment in Diltiazem Market

Figure 5. North America Diltiazem Market – Leading Country Markets (US$ Million)

Figure 6. North America PEST Analysis

Figure 7. Diltiazem Market: Impact Analysis of Drivers and Restraints

Figure 8. North America Diltiazem Market – Revenue Forecast and Analysis – 2020- 2028

Figure 9. Diltiazem Market Share by Product Type 2021 & 2028 (%)

Figure 10. Capsules Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 11. Injection Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 12. Tablet Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 13. Diltiazem Market Share by Application 2021 & 2028 (%)

Figure 14. Angina Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 15. Hypertension Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 16. Others Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 17. North America: Diltiazem Market, by Key Country – Revenue (2021) (USD Million)

Figure 18. North America: Diltiazem Market, by Country, 2021 & 2028 (%)

Figure 19. US Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

Figure 20. Canada Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

Figure 21. Mexico Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

Figure 22. Impact of COVID-19 Pandemic in North American Country Markets

  1. Bausch Health Companies Inc.
  2. Teva Pharmaceutical Industries Ltd
  3. MYLAN N.V.
  4. Pfizer Inc.
  5. Sandoz (Novartis AG)
  6. Sun Pharmaceutical Industries Ltd
  7. Hikma Pharmaceuticals PLC
  8. Zydus Cadila
  9. Glenmark
  10. Athenex

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America diltiazem market.

- Highlights key business priorities in order to assist companies to realign their business strategies.

- The key findings and recommendations highlight crucial progressive industry trends in the North America diltiazem market, thereby allowing players across the value chain to develop effective long-term strategies.

- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.

- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TIPRE00025364
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.